Physician profile
Ted Karl
NPI 1063529501
$3,230.30
in general payments reported to CMS, 2019-2025
24 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $139 · 2021: $515 · 2022: $439 · 2023: $323 · 2024: $726 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $657.54 | 2021-2025 | Simbrinza, Tryptyr, Rocklatan |
| Oyster Point Pharma, INC. | $382.34 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $280.65 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $215.03 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $196.96 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $193.56 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $192.43 | 2019-2024 | Cequa |
| Mallinckrodt Hospital Products INC. | $168.70 | 2021 | |
| Kala Pharmaceuticals, INC. | $153.23 | 2019-2022 | |
| New World Medical,INC. | $95.43 | 2022 | |
| Biotissue Holdings INC. | $93.65 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $90.36 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $87.23 | 2019-2021 | |
| Amgen INC. | $70.50 | 2024-2025 | Tepezza |
| Dompe US, INC. | $48.54 | 2022-2025 | Oxervate |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45.22 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $45.10 | 2019 | |
| Thea Pharma INC. | $44.40 | 2025 | Iyuzeh |
| Apellis Pharmaceuticals, INC. | $41.97 | 2025 | Syfovre |
| Rayner Intraocular Lenses Limited | $32.37 | 2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Eyevance Pharmaceuticals LLC | $29.82 | 2019-2022 | |
| Sight Sciences, INC. | $25.86 | 2022 | |
| Allergan, INC. | $22.22 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $17.19 | 2024 | Amo Phaco Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Karl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.